开发高强度非结核性真菌菌菌剂的预配方开发
Satish G Agrawal1, E Jeffrey North1, Alekha K Dash1
1Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178, USA.
Results in chemistry
|February 23, 2026
概括
新型的英多尔-2-碳胺化合物对非结核性真菌菌菌 (NTM) 感染有前途. 预制剂研究揭示了溶解性和透性的挑战,将它们归类为生物制药分类系统II类药物.
科学领域:
- 药用化学和药物开发 医学化学和药物开发
- 制药科学 制药科学
- 微生物学 微生物学
背景情况:
- 非结核菌 (NTM) 是重要的病原体,特别是在患有COPD或囊性纤维化等潜在肺部疾病的个体中.
- 在临床前模型中,新型的英多尔-2-碳胺 (ICs) 对NTM表现出强大的抗菌活性,包括* Mycobacterium tuberculosis*和* Mycobacterium abscessus*.
- IC化合物因水溶性和透性差而面临挑战,需要高剂量才能有效.
研究的目的:
- 对两种英多尔-2-碳胺 (IC) 化合物N2和N21进行全面的预制研究.
- 描述N2和N21的固态特性和物理化学参数.
- 根据生物制药分类系统 (BCS) 标准,评估潜在的体内吸收和生物可用性挑战.
主要方法:
- 使用扫描电子显微镜 (SEM),差分扫描热量测量 (DSC),热重力测量分析 (TGA),热阶段显微镜 (HSM) 和X射线粉末衍射 (XRD) 进行固态特征.
- 物理化学性质的确定,包括八醇/水分区系数 (LogP),pKa,可溶性,pH稳定性,内在溶解和Caco-2细胞单层透性.
- 对N2和N21的多态性查.
主要成果:
- 两个IC (N2和N21) 都是晶体固体;N21表现出单一的多态性,而N2则没有.
- 化合物具有较差的水溶性 (<0.2 μg/mL) 和高的Caco-2透性 (>18 × 10-6 cm/s),符合生物制药分类系统 (BCS) 的II类.
- N2和N21具有弱酸性,在pH值6.8和pKa值在6.7到7.9之间具有最佳稳定性.
结论:
- 预制剂数据表明N2和N21是BCSII类药物,主要受到水溶性差的限制,这可能会影响体内吸收和生物可用性.
- 这些发现为N2和N21未来的配方开发提供了关键信息,作为NTM感染的潜在治疗方法.
- 成功的配方策略对于推动这些候选药物进入临床试验和最终获得NTM治疗监管批准至关重要.
更多相关视频
相关概念视频
01:28Pulmonary Tuberculosis V
669
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
669
01:28Pulmonary Tuberculosis II
1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
01:28Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
01:26Pulmonary Tuberculosis IV
560
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
560